Predictors of pharmacological treatment outcomes with atomoxetine or methylphenidate in patients with attention-deficit/hyperactivity disorder from China, Egypt, Lebanon, Russian Federation, Taiwan, and United Arab Emirates
Summary Background The reduced availability of data from non‐Western countries limits our ability to understand attention‐deficit/hyperactivity disorder (ADHD) treatment outcomes, specifically, adherence and persistence of ADHD in children and adolescents. This analysis assessed predictors of treatm...
Gespeichert in:
| Veröffentlicht in: | International journal of clinical practice (Esher) 2014-09, Vol.68 (9), p.1152-1160 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1160 |
|---|---|
| container_issue | 9 |
| container_start_page | 1152 |
| container_title | International journal of clinical practice (Esher) |
| container_volume | 68 |
| creator | Treuer, T. Feng, Q. Desaiah, D. Altin, M. Wu, S. El-Shafei, A. Serebryakova, E. Gado, M. Faries, D. |
| description | Summary
Background
The reduced availability of data from non‐Western countries limits our ability to understand attention‐deficit/hyperactivity disorder (ADHD) treatment outcomes, specifically, adherence and persistence of ADHD in children and adolescents. This analysis assessed predictors of treatment outcomes in a non‐Western cohort of patients with ADHD treated with atomoxetine or methylphenidate.
Methods
Data from a 12‐month, prospective, observational study in outpatients aged 6–17 years treated with atomoxetine (N = 234) or methylphenidate (N = 221) were analysed post hoc to determine potential predictors of treatment outcomes. Participating countries included the Russian Federation, China, Taiwan, Egypt, United Arab Emirates and Lebanon. Factors associated with remission were analysed with stepwise multiple logistic regression and classification and regression trees (CART). Cox proportional hazards models with propensity score adjustment assessed differences in atomoxetine persistence among initial‐dose cohorts.
Results
In patients treated with atomoxetine who had available dosing information (N = 134), Cox proportional hazards revealed lower ( |
| doi_str_mv | 10.1111/ijcp.12437 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1561035624</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3423998811</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5017-7d1c6a1abccf3b4b11dc25a9f0de9530720ce7c20d36d831d854041b44f2b863</originalsourceid><addsrcrecordid>eNp9kc1u1DAURiMEomVgwwMgS2wQmrR2HCfpsoymPzCCCg3q0nLsm8ZDYqe2wzRPy6vgYdpZsMCb6yud79OVTpK8JfiExHeqN3I4IVlOy2fJMSnzLI0LeR7_tKhShik5Sl55v8E4Y6zCL5OjLC8xzbLqOPl940BpGazzyDZoaIXrhbSdvdNSdCg4EKEHE5Adg7Q9eLTVoUUi2N4-QNAGkHWoh9BO3dCC0UoEQNqgQQQdcwc-xEVbkypotNThtJ0GcEIG_UuHCSntrVPgUONsjxatNmKOlnfTEOZoBbUw1szR99F7LQy6gEiKXdscrYXeijiFUeiH0QEUOneiRsteRwT86-RFIzoPbx7nLFlfLNeLq3T17fJ6cb5KJcOkTEtFZCGIqKVsaJ3XhCiZMXHWYAVnjOIywxJKmWFFC1VRoiqW45zUed5kdVXQWfJhXzs4ez-CD7zXXkLXCQN29JywgmDKiihplrz_B93Y0Zl43I6KWipa7KiPe0o6672Dhg9O98JNnGC-s8531vlf6xF-91g51j2oA_qkOQJkD2x1B9N_qvj158XNU2m6z2gf4OGQEe4nL0paMn779ZLjnH35dFXc8pL-ATa-y9Y</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1560328364</pqid></control><display><type>article</type><title>Predictors of pharmacological treatment outcomes with atomoxetine or methylphenidate in patients with attention-deficit/hyperactivity disorder from China, Egypt, Lebanon, Russian Federation, Taiwan, and United Arab Emirates</title><source>Wiley Online Library - AutoHoldings Journals</source><source>MEDLINE</source><creator>Treuer, T. ; Feng, Q. ; Desaiah, D. ; Altin, M. ; Wu, S. ; El-Shafei, A. ; Serebryakova, E. ; Gado, M. ; Faries, D.</creator><creatorcontrib>Treuer, T. ; Feng, Q. ; Desaiah, D. ; Altin, M. ; Wu, S. ; El-Shafei, A. ; Serebryakova, E. ; Gado, M. ; Faries, D.</creatorcontrib><description>Summary
Background
The reduced availability of data from non‐Western countries limits our ability to understand attention‐deficit/hyperactivity disorder (ADHD) treatment outcomes, specifically, adherence and persistence of ADHD in children and adolescents. This analysis assessed predictors of treatment outcomes in a non‐Western cohort of patients with ADHD treated with atomoxetine or methylphenidate.
Methods
Data from a 12‐month, prospective, observational study in outpatients aged 6–17 years treated with atomoxetine (N = 234) or methylphenidate (N = 221) were analysed post hoc to determine potential predictors of treatment outcomes. Participating countries included the Russian Federation, China, Taiwan, Egypt, United Arab Emirates and Lebanon. Factors associated with remission were analysed with stepwise multiple logistic regression and classification and regression trees (CART). Cox proportional hazards models with propensity score adjustment assessed differences in atomoxetine persistence among initial‐dose cohorts.
Results
In patients treated with atomoxetine who had available dosing information (N = 134), Cox proportional hazards revealed lower (< 0.5 mg/kg) initial dose was significantly associated with shorter medication persistence (p < 0.01). multiple logistic regression analysis revealed greater rates of remission for atomoxetine‐treated patients were associated with age (older), country (United Arab Emirates) and gender (female) (all p < 0.05). CART analysis confirmed older age and lack of specific phobias were associated with greater remission rates. For methylphenidate, greater baseline weight (highly correlated with the age factor found for atomoxetine) and prior atomoxetine use were associated with greater remission rates.
Conclusions
These findings may help clinicians assess factors upon initiation of ADHD treatment to improve course prediction, proper dosing and treatment adherence and persistence.
Trial registration
Observational study, therefore no registration.</description><identifier>ISSN: 1368-5031</identifier><identifier>EISSN: 1742-1241</identifier><identifier>DOI: 10.1111/ijcp.12437</identifier><identifier>PMID: 24703228</identifier><language>eng</language><publisher>England: Blackwell Publishing Ltd</publisher><subject>Adolescent ; Atomoxetine Hydrochloride - therapeutic use ; Attention Deficit Disorder with Hyperactivity - drug therapy ; Attention Deficit Hyperactivity Disorder ; China ; Clinical outcomes ; Drug therapy ; Egypt ; Female ; Humans ; Lebanon ; Male ; Methylphenidate - therapeutic use ; Propylamines - therapeutic use ; Prospective Studies ; Psychopharmacology ; Russia ; Taiwan ; Treatment Outcome ; United Arab Emirates</subject><ispartof>International journal of clinical practice (Esher), 2014-09, Vol.68 (9), p.1152-1160</ispartof><rights>2014 John Wiley & Sons Ltd</rights><rights>2014 John Wiley & Sons Ltd.</rights><rights>Copyright © 2014 John Wiley & Sons Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5017-7d1c6a1abccf3b4b11dc25a9f0de9530720ce7c20d36d831d854041b44f2b863</citedby><cites>FETCH-LOGICAL-c5017-7d1c6a1abccf3b4b11dc25a9f0de9530720ce7c20d36d831d854041b44f2b863</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fijcp.12437$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fijcp.12437$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24703228$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Treuer, T.</creatorcontrib><creatorcontrib>Feng, Q.</creatorcontrib><creatorcontrib>Desaiah, D.</creatorcontrib><creatorcontrib>Altin, M.</creatorcontrib><creatorcontrib>Wu, S.</creatorcontrib><creatorcontrib>El-Shafei, A.</creatorcontrib><creatorcontrib>Serebryakova, E.</creatorcontrib><creatorcontrib>Gado, M.</creatorcontrib><creatorcontrib>Faries, D.</creatorcontrib><title>Predictors of pharmacological treatment outcomes with atomoxetine or methylphenidate in patients with attention-deficit/hyperactivity disorder from China, Egypt, Lebanon, Russian Federation, Taiwan, and United Arab Emirates</title><title>International journal of clinical practice (Esher)</title><addtitle>Int J Clin Pract</addtitle><description>Summary
Background
The reduced availability of data from non‐Western countries limits our ability to understand attention‐deficit/hyperactivity disorder (ADHD) treatment outcomes, specifically, adherence and persistence of ADHD in children and adolescents. This analysis assessed predictors of treatment outcomes in a non‐Western cohort of patients with ADHD treated with atomoxetine or methylphenidate.
Methods
Data from a 12‐month, prospective, observational study in outpatients aged 6–17 years treated with atomoxetine (N = 234) or methylphenidate (N = 221) were analysed post hoc to determine potential predictors of treatment outcomes. Participating countries included the Russian Federation, China, Taiwan, Egypt, United Arab Emirates and Lebanon. Factors associated with remission were analysed with stepwise multiple logistic regression and classification and regression trees (CART). Cox proportional hazards models with propensity score adjustment assessed differences in atomoxetine persistence among initial‐dose cohorts.
Results
In patients treated with atomoxetine who had available dosing information (N = 134), Cox proportional hazards revealed lower (< 0.5 mg/kg) initial dose was significantly associated with shorter medication persistence (p < 0.01). multiple logistic regression analysis revealed greater rates of remission for atomoxetine‐treated patients were associated with age (older), country (United Arab Emirates) and gender (female) (all p < 0.05). CART analysis confirmed older age and lack of specific phobias were associated with greater remission rates. For methylphenidate, greater baseline weight (highly correlated with the age factor found for atomoxetine) and prior atomoxetine use were associated with greater remission rates.
Conclusions
These findings may help clinicians assess factors upon initiation of ADHD treatment to improve course prediction, proper dosing and treatment adherence and persistence.
Trial registration
Observational study, therefore no registration.</description><subject>Adolescent</subject><subject>Atomoxetine Hydrochloride - therapeutic use</subject><subject>Attention Deficit Disorder with Hyperactivity - drug therapy</subject><subject>Attention Deficit Hyperactivity Disorder</subject><subject>China</subject><subject>Clinical outcomes</subject><subject>Drug therapy</subject><subject>Egypt</subject><subject>Female</subject><subject>Humans</subject><subject>Lebanon</subject><subject>Male</subject><subject>Methylphenidate - therapeutic use</subject><subject>Propylamines - therapeutic use</subject><subject>Prospective Studies</subject><subject>Psychopharmacology</subject><subject>Russia</subject><subject>Taiwan</subject><subject>Treatment Outcome</subject><subject>United Arab Emirates</subject><issn>1368-5031</issn><issn>1742-1241</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kc1u1DAURiMEomVgwwMgS2wQmrR2HCfpsoymPzCCCg3q0nLsm8ZDYqe2wzRPy6vgYdpZsMCb6yud79OVTpK8JfiExHeqN3I4IVlOy2fJMSnzLI0LeR7_tKhShik5Sl55v8E4Y6zCL5OjLC8xzbLqOPl940BpGazzyDZoaIXrhbSdvdNSdCg4EKEHE5Adg7Q9eLTVoUUi2N4-QNAGkHWoh9BO3dCC0UoEQNqgQQQdcwc-xEVbkypotNThtJ0GcEIG_UuHCSntrVPgUONsjxatNmKOlnfTEOZoBbUw1szR99F7LQy6gEiKXdscrYXeijiFUeiH0QEUOneiRsteRwT86-RFIzoPbx7nLFlfLNeLq3T17fJ6cb5KJcOkTEtFZCGIqKVsaJ3XhCiZMXHWYAVnjOIywxJKmWFFC1VRoiqW45zUed5kdVXQWfJhXzs4ez-CD7zXXkLXCQN29JywgmDKiihplrz_B93Y0Zl43I6KWipa7KiPe0o6672Dhg9O98JNnGC-s8531vlf6xF-91g51j2oA_qkOQJkD2x1B9N_qvj158XNU2m6z2gf4OGQEe4nL0paMn779ZLjnH35dFXc8pL-ATa-y9Y</recordid><startdate>201409</startdate><enddate>201409</enddate><creator>Treuer, T.</creator><creator>Feng, Q.</creator><creator>Desaiah, D.</creator><creator>Altin, M.</creator><creator>Wu, S.</creator><creator>El-Shafei, A.</creator><creator>Serebryakova, E.</creator><creator>Gado, M.</creator><creator>Faries, D.</creator><general>Blackwell Publishing Ltd</general><general>Hindawi Limited</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7T5</scope><scope>7TK</scope><scope>7TS</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope></search><sort><creationdate>201409</creationdate><title>Predictors of pharmacological treatment outcomes with atomoxetine or methylphenidate in patients with attention-deficit/hyperactivity disorder from China, Egypt, Lebanon, Russian Federation, Taiwan, and United Arab Emirates</title><author>Treuer, T. ; Feng, Q. ; Desaiah, D. ; Altin, M. ; Wu, S. ; El-Shafei, A. ; Serebryakova, E. ; Gado, M. ; Faries, D.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5017-7d1c6a1abccf3b4b11dc25a9f0de9530720ce7c20d36d831d854041b44f2b863</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Adolescent</topic><topic>Atomoxetine Hydrochloride - therapeutic use</topic><topic>Attention Deficit Disorder with Hyperactivity - drug therapy</topic><topic>Attention Deficit Hyperactivity Disorder</topic><topic>China</topic><topic>Clinical outcomes</topic><topic>Drug therapy</topic><topic>Egypt</topic><topic>Female</topic><topic>Humans</topic><topic>Lebanon</topic><topic>Male</topic><topic>Methylphenidate - therapeutic use</topic><topic>Propylamines - therapeutic use</topic><topic>Prospective Studies</topic><topic>Psychopharmacology</topic><topic>Russia</topic><topic>Taiwan</topic><topic>Treatment Outcome</topic><topic>United Arab Emirates</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Treuer, T.</creatorcontrib><creatorcontrib>Feng, Q.</creatorcontrib><creatorcontrib>Desaiah, D.</creatorcontrib><creatorcontrib>Altin, M.</creatorcontrib><creatorcontrib>Wu, S.</creatorcontrib><creatorcontrib>El-Shafei, A.</creatorcontrib><creatorcontrib>Serebryakova, E.</creatorcontrib><creatorcontrib>Gado, M.</creatorcontrib><creatorcontrib>Faries, D.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Physical Education Index</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of clinical practice (Esher)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Treuer, T.</au><au>Feng, Q.</au><au>Desaiah, D.</au><au>Altin, M.</au><au>Wu, S.</au><au>El-Shafei, A.</au><au>Serebryakova, E.</au><au>Gado, M.</au><au>Faries, D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Predictors of pharmacological treatment outcomes with atomoxetine or methylphenidate in patients with attention-deficit/hyperactivity disorder from China, Egypt, Lebanon, Russian Federation, Taiwan, and United Arab Emirates</atitle><jtitle>International journal of clinical practice (Esher)</jtitle><addtitle>Int J Clin Pract</addtitle><date>2014-09</date><risdate>2014</risdate><volume>68</volume><issue>9</issue><spage>1152</spage><epage>1160</epage><pages>1152-1160</pages><issn>1368-5031</issn><eissn>1742-1241</eissn><abstract>Summary
Background
The reduced availability of data from non‐Western countries limits our ability to understand attention‐deficit/hyperactivity disorder (ADHD) treatment outcomes, specifically, adherence and persistence of ADHD in children and adolescents. This analysis assessed predictors of treatment outcomes in a non‐Western cohort of patients with ADHD treated with atomoxetine or methylphenidate.
Methods
Data from a 12‐month, prospective, observational study in outpatients aged 6–17 years treated with atomoxetine (N = 234) or methylphenidate (N = 221) were analysed post hoc to determine potential predictors of treatment outcomes. Participating countries included the Russian Federation, China, Taiwan, Egypt, United Arab Emirates and Lebanon. Factors associated with remission were analysed with stepwise multiple logistic regression and classification and regression trees (CART). Cox proportional hazards models with propensity score adjustment assessed differences in atomoxetine persistence among initial‐dose cohorts.
Results
In patients treated with atomoxetine who had available dosing information (N = 134), Cox proportional hazards revealed lower (< 0.5 mg/kg) initial dose was significantly associated with shorter medication persistence (p < 0.01). multiple logistic regression analysis revealed greater rates of remission for atomoxetine‐treated patients were associated with age (older), country (United Arab Emirates) and gender (female) (all p < 0.05). CART analysis confirmed older age and lack of specific phobias were associated with greater remission rates. For methylphenidate, greater baseline weight (highly correlated with the age factor found for atomoxetine) and prior atomoxetine use were associated with greater remission rates.
Conclusions
These findings may help clinicians assess factors upon initiation of ADHD treatment to improve course prediction, proper dosing and treatment adherence and persistence.
Trial registration
Observational study, therefore no registration.</abstract><cop>England</cop><pub>Blackwell Publishing Ltd</pub><pmid>24703228</pmid><doi>10.1111/ijcp.12437</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1368-5031 |
| ispartof | International journal of clinical practice (Esher), 2014-09, Vol.68 (9), p.1152-1160 |
| issn | 1368-5031 1742-1241 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1561035624 |
| source | Wiley Online Library - AutoHoldings Journals; MEDLINE |
| subjects | Adolescent Atomoxetine Hydrochloride - therapeutic use Attention Deficit Disorder with Hyperactivity - drug therapy Attention Deficit Hyperactivity Disorder China Clinical outcomes Drug therapy Egypt Female Humans Lebanon Male Methylphenidate - therapeutic use Propylamines - therapeutic use Prospective Studies Psychopharmacology Russia Taiwan Treatment Outcome United Arab Emirates |
| title | Predictors of pharmacological treatment outcomes with atomoxetine or methylphenidate in patients with attention-deficit/hyperactivity disorder from China, Egypt, Lebanon, Russian Federation, Taiwan, and United Arab Emirates |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T04%3A46%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Predictors%20of%20pharmacological%20treatment%20outcomes%20with%20atomoxetine%20or%20methylphenidate%20in%20patients%20with%20attention-deficit/hyperactivity%20disorder%20from%20China,%20Egypt,%20Lebanon,%20Russian%20Federation,%20Taiwan,%20and%20United%20Arab%20Emirates&rft.jtitle=International%20journal%20of%20clinical%20practice%20(Esher)&rft.au=Treuer,%20T.&rft.date=2014-09&rft.volume=68&rft.issue=9&rft.spage=1152&rft.epage=1160&rft.pages=1152-1160&rft.issn=1368-5031&rft.eissn=1742-1241&rft_id=info:doi/10.1111/ijcp.12437&rft_dat=%3Cproquest_cross%3E3423998811%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1560328364&rft_id=info:pmid/24703228&rfr_iscdi=true |